COMP <GO>
MEDP vs MRK // 10Y YIELD & FRED MACRO BETA
Medpace Holdings Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: MEDP 5
— MRK 9
▲ 10Y YIELD & FRED MACRO BETA LEADER: MEDP
LAST: $652.01 (-3.77%) • MKT CAP: $18.95B
macro-sensitivity
1.00
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
macro-sensitivity
0.92
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MEDP VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MEDP | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.90% | 20.70% | +7.20 | MEDP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.0x | 15.3x | +18.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.60% | 3.42% | +0.18 | MEDP | /fcf-yield <GO> |
| Operating Margin | 21.10% | 34.30% | -13.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | 17.80% | 28.10% | -10.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 1.30% | +18.70 | MEDP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.13 | 5.19 | +3.94 | MEDP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.6 | 56.9 | -2.24 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.00 | 0.92 | +0.08 | MEDP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.3x | 18.4x | +16.90 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.95B | $361.02B | -$342.07B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MEDP REV | MRK REV | MEDP GROSS % | MRK GROSS % | MEDP FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $65.01B | 44.0% | 74.8% | $681.9M | $12.36B |
| FY 2024 | $2.11B | $64.17B | 44.0% | 76.3% | $572.3M | $18.10B |
| FY 2023 | $1.89B | $60.12B | 44.0% | 44.0% | $348.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MEDP // BETA 1.00
MRK // BETA 0.92